Serum Levels of the MCP-1 Chemokine in Patients With Ischemic Stroke and Myocardial InfarctionReportar como inadecuado

Serum Levels of the MCP-1 Chemokine in Patients With Ischemic Stroke and Myocardial Infarction - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Mediators of Inflammation - Volume 2005 2005, Issue 3, Pages 175-179

Department of Immunology, Palacký University Olomouc, Olomouc 77520, Czech Republic

Institute of Molecular Biology of the National Academy of Sciences of Armenia, Yerevan, Armenia

Department of Internal Medicine I, Palacký University and Faculty Hospital Olomouc, Olomouc 77520, Czech Republic

Received 4 February 2005; Accepted 22 February 2005

Copyright © 2005 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Chemokine-driven migration of inflammatory cells has been implicated in pathogenesis of atherosclerosis-associated conditions such as ischemic stroke and myocardial infarction. In this study, a candidate chemokine, monocyte chemoattractant protein MCP-1, was investigated in patients with both aforementioned manifestations of atheroslerotic inflammation. MCP-1 levels in serum were determined by ELISA in 40 healthy, control subjects C, 40 patients with ischemic stroke IS, and in 64 patients with myocardial infarction MI. Statistical analysis utilised Mann-Whitney test, Fisher-s exact test, and Spearman-s rank correlation P<.05. In comparison to control subjects C; median-interquartile range: 239-126 pg-mL, MCP-1 serum levels were increased in both investigated patient cohortsIS: 384-370, P<.001; MI: 360-200, P<.002. There was a substantial variability of MCP-1 serum levels, especially in theIS group. No relationship was observed between chemokine levels and atherosclerosis risk factors hypertension, diabetes, smoking, and alcohol consumption, and MCP-1 was also not related to age or gender. Elevation of MCP-1 in circulation of patients with atherosclerosis-associated complications implicates this CC chemokine ligand CCL2 in inflammatory processes, which contribute to pathogenesis of myocardial infarction and ischemic stroke. Further investigations, including patient stratification, are however necessary to evaluate if MCP-1 can be utilised for clinical management of patients with these diseases.

Autor: A. Arakelyan, J. Petrkova, Z. Hermanova, A. Boyajyan, J. Lukl, and M. Petrek



Documentos relacionados